Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
7 min read
AOBiome Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
AOBiome Therapeutics, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Angion Biomedica Corp. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Angion Biomedica Corp. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Armatus Bio LLC Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Armatus Bio LLC 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Ao Chen Sheng Wu ( Yun Nan ) You Xian Gong Si Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Ao Chen Sheng Wu ( Yun Nan ) You Xian Gong Si 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Ampersand Biomedicines, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Ampersand Biomedicines, Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Alchemedicine KK Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Alchemedicine KK 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
AimedBio Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
AimedBio Inc. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Ailux Biologics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Ailux Biologics 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
8 min read
Affibody Medical AB Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Affibody Medical AB 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
AiCuris GmbH & Co. KG Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
AiCuris GmbH & Co. KG 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
AffyXell Therapeutics Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
AffyXell Therapeutics Co., Ltd. 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
Latest Hotspot
7 min read
Agency for Science, Technology & Research Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
4 August 2026
Agency for Science, Technology & Research 2026 BD opportunity scan covering pipeline assets, ownership, stage, transaction precedents, financial signals, IP risk and outreach priorities.
Read →
<
1
<<
1651
1652
1653
1654
1655
>>
2926
>